A Phase 1, Single Dose, Fixed Sequence Study To Estimate The Absolute Bioavailability Of Dacomitinib (PF-00299804) By Comparing Oral To Intravenous Administration In Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 19 Oct 2015
Price : $35 *
At a glance
- Drugs Dacomitinib (Primary) ; Dacomitinib (Primary)
- Indications Glioblastoma; Head and neck cancer; Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Pfizer
- 01 Jun 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 06 May 2013 Planned end date changed from 1 May 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 03 Apr 2013 Planned initiation date changed from 1 Mar 2013 to 1 Apr 2013 as reported by ClinicalTrials.gov.